Our work is entirely funded by private donations – we receive no money from government. Your money will help us continue funding research into vitiligo and supporting people affected by the condition.
Official Title: Topical Ruxolitinib Evaluation in Vitiligo Study 1 (TRuE-V1): A Phase 3, Double-Blind, Randomized, Vehicle-Controlled, Efficacy and Safety Study of Ruxolitinib Cream Followed by an Extension Period in Participants With Vitiligo.
In Brief: Participants will receive ruxolitinib cream or placebo for 24 weeks, after which they will be offered the opportunity to continue in the treatment extension period. Participants initially randomized to placebo will be crossed over to active drug, and participants treated with ruxolitinib cream will receive an additional 28 weeks of treatment with ruxolitinib cream.
Ages eligible: 12 Years and older
- Center For Dermatology and Plastic Surgery: Scottsdale, Arizona, United States, 85260
- Burke Pharmaceutical Research: Hot Springs, Arkansas, United States, 71913
- Marvel Clinical Research: Huntington Beach, California, United States, 92647
- Rady Children's Hospital: San Diego, California, United States, 92123
- Clinical Research Center of Connecticut: Danbury, Connecticut, United States, 06810
- Harmony Medical Research Institute: Hialeah, Florida, United States, 33016
- San Marcus Research Clinic: Miami Lakes, Florida, United States, 33014
- ForCare Medical Center: Tampa, Florida, United States, 33613
- Metabolic Research Institute: West Palm Beach, Florida, United States, 33401
- Northwestern University, Chicago, Illinois, United States, 60611
- Great Lakes Research Group: Bay City, Michigan, United States, 48706
- Washington University in St Louis: Saint Louis, Missouri, United States, 63141
- SUNY Downstate Medical Center: Brooklyn, New York, United States, 11203
- Forest Hills Dermatology Group: Forest Hills, New York, United States, 11375
- Buka Dermatology: New York, New York, United States, 10012
- M3 Wake Research: Raleigh, North Carolina, United States, 27612
- Wake Forest University Health Sciences: Winston-Salem, North Carolina, United States, 27157
- KGL Skin Study Center: Broomall, Pennsylvania, United States, 19008
- Dermatology Associates of Plymouth Meeting: PC Plymouth Meeting, Pennsylvania, United States, 19462
- Palmetto Clinical Trial Services: Anderson, South Carolina, United States, 29621
- International Clinical Research-Tennessee: Murfreesboro, Tennessee, United States, 37130
- Progressive Clinical Research - San Antonio: San Antonio, Texas, United States, 78213
- Dermatology Clinical Research Center of San Antonio; San Antonio, Texas, United States, 78229
- Dermatology Specialists of Spokane: Spokane, Washington, United States, 99202
Status: Active, recruiting
Start date: September 20, 2019
Completion date (estimated): November 30, 2021
ClinicalTrials.gov identifier: NCT04052425
Contacts: To learn more about this study, you or your doctor may contact Incyte Corporation Call Center by phone +800 00027423 or email email@example.com. Please refer to this study by its NCT number.
- What are risks of oral and topical corticosteroids?
Corticosteroid drugs (like hydrocortisone, and others) are often used for treating vitiligo. By mimicing the effects of hormones your body produces naturally in your adrenal gla...
- Can chemicals cause vitiligo?
It’s important to remember there are multiple factors involved in vitiligo onset, including genetic predisposition, living and working environments, and exposure to certain chem...
- Which diseases most commonly accompany vitiligo?
According to a 10-year study, vitiligo patients have a statistically significant higher prevalence of other autoimmune conditions and dermatological disorders: hypothyroidism...
Though it is not always easy to treat vitiligo, there is much to be gained by clearly understanding the diagnosis, the future implications, treatment options and their outcomes.
Many people deal with vitiligo while remaining in the public eye, maintaining a positive outlook, and having a successful career.Copyright (C) Bodolóczki Júlia
By taking a little time to fill in the anonymous questionnaire, you can help researchers better understand and fight vitiligo.